Mehmet Asim Bilen, MD

home / authors / mehmet-asim-bilen-md

Articles

Choosing a First-Line Combination Treatment Regimen for Renal Cell Carcinoma

Mehmet Asim Bilen, MD;Marie Carlo, MD;Robert J. Motzer, MD;Moshe Ornstein, MD, MA;Brian I. Rini, MD;Rana R. McKay, MD;Tom Powles, MBBS, MRCP, MD

April 4th 2022

Drs Rana McKay and Tom Powles debate the merits of different first-line combination treatment regimens for renal cell carcinoma.

Second-Line Therapy Following a TKI/IO Regimen for Favorable-Risk RCC

Robert J. Motzer, MD;David Aggen, MD, PhD;Robert S. Alter, MD;Mehmet Asim Bilen, MD;Brian I. Rini, MD

April 4th 2022

A brief discussion on available treatment options after patients progress following frontline TKI/IO therapy with favorable-risk renal cell carcinoma.

Favorable-Risk RCC: AE Management and Dosing With TKI/IO Therapy

Robert J. Motzer, MD;David Aggen, MD, PhD;Robert S. Alter, MD;Mehmet Asim Bilen, MD;Brian I. Rini, MD

April 4th 2022

A comprehensive review of the adverse event profiles of TKI/IO regimens used in favorable-risk renal cell carcinoma and how these can be managed with dose adjustment.

Biomarker Testing: Methodologies, Sample Types, and Emerging Data

Mehmet Asim Bilen, MD

March 30th 2022

Mehmet Asim Bilen, MD weighs in on various biomarker testing methodologies, sample considerations, and emerging data on novel biomarkers.

Metastatic RCC: Prognosis and Recent Advances in Care

Mehmet Asim Bilen, MD

March 30th 2022

Mehmet Asim Bilen, MD comments on the prognosis of patients with metastatic RCC and how recent advances have improved outcomes.

Choosing Appropriate Patients and Dosing for Lenvatinib + Pembrolizumab in RCC

Robert J. Motzer, MD;David Aggen, MD, PhD;Robert S. Alter, MD;Mehmet Asim Bilen, MD;Brian I. Rini, MD

March 28th 2022

Expert insights on selecting the appropriate patients and dose for treatment with the lenvatinib plus pembrolizumab regimen in patients with renal cell carcinoma.

Patient Profile 1: Favorable-Risk RCC Treated With Lenvatinib + Pembrolizumab

Robert J. Motzer, MD;David Aggen, MD, PhD;Robert S. Alter, MD;Mehmet Asim Bilen, MD;Brian I. Rini, MD

March 28th 2022

Experts open their discussion on RCC by reviewing the clinical scenario of a patient with favorable-risk disease who is treated with the TKI/IO regimen of lenvatinib and pembrolizumab.

Impressions of Data and Results from the CLEAR Trial

Mehmet Asim Bilen, MD;Marie Carlo, MD;Robert J. Motzer, MD;Moshe Ornstein, MD, MA;Brian I. Rini, MD;Rana R. McKay, MD;Tom Powles, MBBS, MRCP, MD

March 18th 2022

Oncologists give their initial impressions about the results of a clinical trial studying doublet combination therapies for advanced renal cell carcinoma.

Background: Lenvatinib + Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

Mehmet Asim Bilen, MD;Marie Carlo, MD;Robert J. Motzer, MD;Moshe Ornstein, MD, MA;Brian I. Rini, MD;Rana R. McKay, MD;Tom Powles, MBBS, MRCP, MD

March 18th 2022

Robert J. Motzer, MD, presents data examined in the article, “Lenvatinib Plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.”

Radium-223: Optimizing Treatment and Research of Osteoblastic Bone Metastasis

Shi-Ming Tu, MD;Mehmet Asim Bilen, MD;Sue-Hwa Lin, PhD

July 15th 2015

Elucidation of the underlying mechanisms of action for Ra-223 will soon expand its clinical utility with respect to improved patient selection and integrated bone-targeted therapies.

<1 2